Re PurposeDrugs (https://re Purposedrugs.org/) 是一个综合性门户网站，它将独特的药物适应症数据库与机器学习 (ML) 预测器相结合，以发现已批准以及在研单药和联合疗法的新药物适应症关联。该平台提供有关 25 个适应症类别（包括肿瘤和心血管疾病）的治疗状态、疾病适应症和临床试验的详细信息。当前版本包含 4314 种化合物（已批准、终止或研究）和 161 种药物组合，涉及 1756 种适应症/病症，总计 28 148 个药物-疾病对。通过利用已批准和失败的适应症的数据，Re PurposeDrugs 为新药物疾病适应症的批准潜力提供基于机器学习的预测，无论是单一疗法还是组合疗法，在交叉验证中表现出较高的预测准确性。机器学习预测器的有效性通过大量现实案例研究得到验证，证明了其预测能力，可以准确识别重新利用的候选者，并且未来获得批准的可能性很高。据我们所知，Re PurposeDrugs 门户网站是第一个集成数据库和基于 ML 的预测器，用于交互式探索和预测单一药物和组合药物跨适应症的批准可能性。鉴于其广泛的适应症领域和治疗选择，我们预计它将加速许多未来的药物再利用项目。© 作者 2024。由牛津大学出版社出版。

RepurposeDrugs (https://repurposedrugs.org/) is a comprehensive web-portal that combines a unique drug indication database with a machine learning (ML) predictor to discover new drug-indication associations for approved as well as investigational mono and combination therapies. The platform provides detailed information on treatment status, disease indications and clinical trials across 25 indication categories, including neoplasms and cardiovascular conditions. The current version comprises 4314 compounds (approved, terminated or investigational) and 161 drug combinations linked to 1756 indications/conditions, totaling 28 148 drug-disease pairs. By leveraging data on both approved and failed indications, RepurposeDrugs provides ML-based predictions for the approval potential of new drug-disease indications, both for mono- and combinatorial therapies, demonstrating high predictive accuracy in cross-validation. The validity of the ML predictor is validated through a number of real-world case studies, demonstrating its predictive power to accurately identify repurposing candidates with a high likelihood of future approval. To our knowledge, RepurposeDrugs web-portal is the first integrative database and ML-based predictor for interactive exploration and prediction of both single-drug and combination approval likelihood across indications. Given its broad coverage of indication areas and therapeutic options, we expect it accelerates many future drug repurposing projects.© The Author(s) 2024. Published by Oxford University Press.